Synonym
BMS-933043; BMS 933043; BMS933043.
IUPAC/Chemical Name
(2R)-N-(6-(1H-imidazol-1-yl)-4-pyrimidinyl)-4'H-spiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxazol]-2'-amine
InChi Key
RLXBHTUZCPORKT-INIZCTEOSA-N
InChi Code
InChI=1S/C16H19N7O/c1-4-22-5-2-12(1)16(9-22)8-18-15(24-16)21-13-7-14(20-10-19-13)23-6-3-17-11-23/h3,6-7,10-12H,1-2,4-5,8-9H2,(H,18,19,20,21)/t16-/m0/s1
SMILES Code
C1(CC2)[C@@]3(OC(NC4=NC=NC(N5C=CN=C5)=C4)=NC3)CN2CC1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
325.38
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Bristow LJ, Easton AE, Li YW, Sivarao DV, Lidge R, Jones KM, Post-Munson D,
Daly C, Lodge NJ, Gallagher L, Molski T, Pieschl R, Chen P, Hendricson A,
Westphal R, Cook J, Iwuagwu C, Morgan D, Benitex Y, King D, Macor JE, Zaczek R,
Olson R. The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043,
Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia.
PLoS One. 2016 Jul 28;11(7):e0159996. doi: 10.1371/journal.pone.0159996. PubMed
PMID: 27467081; PubMed Central PMCID: PMC4965148.
2. BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia
Dalton KingChristiana IwuagwuJim CookIvar M. McDonaldRobert MateF. Christopher ZusiMatthew D. HillHaiquan FangRulin ZhaoBei WangAmy E. EastonRegina MillerDebra Post-MunsonRonald J. KnoxLizbeth GallagherRyan WestphalThaddeus MolskiJingsong FanWendy ClarkeYulia BenitexKimberley A. LentzRex DentonDaniel MorganRobert ZaczekNicholas J. LodgeLinda J. BristowJohn E. MacorRichard E. Olson
Publication Date (Web): February 8, 2017 (Letter)
DOI: 10.1021/acsmedchemlett.7b00032
